期刊文献+

ⅢA(N2)期非小细胞肺癌完全切除术后影响预后和局部复发的因素 被引量:2

原文传递
导出
摘要 非小细胞肺癌(non-small cell lung carcinoma,NSCLC)约占全部肺癌的80%。据2009肺癌国际分期,ⅢA(N2)期 NSCLC包含分期为T1~3N 2M 0期,即病理诊断为原发性NSCLC同时伴隆突下淋巴结和(或)同侧纵隔淋巴结转移者。ⅢA(N2)期NSCLC所占比例约20%,手术是国内常用的治疗方法。根据ⅢA期NSCLC完全切除术后治疗失败表型看, 局部区域复发率为23%~33%,远处转移率在50%以上。研究报道ⅢA(N2)期 NSCLC 完全切除术后5年生存率在6%~35%, 完全手术切除后患者是一个异质性明显的疾病组合, 不同临床和病理因素可能决定了不同预后及不同治疗策略。目前临床上进行了广泛的研究以明确可能影响生存或局部复发的预后因素, 以便对N2期患者进一步细分为预后同质性良好的亚组, 有助于指导术后治疗的个体化实施。文献中报道的影响ⅢA(N2)期NSCLC完全手术切除后生存和局部复发的临床或病理因素的预测价值仍存在争议, 各研究结果间不尽相同。笔者从生存和局部区域复发两方面综述ⅢA(N2)期NSCLC完全切除术后相关的临床和病理预后因素, 为指导术后辅助治疗提供参考依据。
作者 冯雯 傅小龙
出处 《中华放射肿瘤学杂志》 CSCD 北大核心 2013年第1期60-63,共4页 Chinese Journal of Radiation Oncology
  • 相关文献

参考文献40

  • 1Detterbeck FC, Boffa DJ, Tanoue LT, et al. The new lung cancer staging system. Chest,2009,136:260-271.
  • 2Goya T, Asamura HI Yoshimura H, et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer,2005,50:227-234.
  • 3Wagner H. Postoperative adjuvant therapy for patients with resected non-small cell lung cancer: still controversial after all these years. Chest ,2000,117 : 110-118.
  • 4Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol, 2000,18:2981- 2989.
  • 5Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Clinical prognostic factors in surgically treated stage -IA-N2 non-small cell lung cancer: analysis of the literature. Lung Cancer, 1998,19:3- 13.
  • 6Detterbeck F. What to do with" surprise" N2 ? Intraoperative . management of patients with non-small cell lung cancer. J Thorac Onco1,2008 ,3 :289-302.
  • 7Ichinose Y, Kato H, Koike T, et al. Overall survival and local recurrence of 406 completely resected stage ⅢA-N2 non-small cell lung cancer patients: questionnaire survey of the Japan clinical oncology group to plan for clinical trials. Lung Cancer, 2001,34: 29-36.
  • 8Lally BE, Zeherman D, Colasanto JM, et al. Postoperative radiotherapy for stage Ⅱ or Ⅲ non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol, 2006,24 : 2998 -3006.
  • 9Miller DL, McManus KG, Allen MS, et al. Results of surgical resection of patients with N2 non-small cell lung cancer. Ann Thorac Surg, 1994,57 : 1095-1101.
  • 10Keller SM;Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage Ⅱ or ⅢA non-small-cell lung cancer. NEJ Med,2000,3d3: 1217-1222.

同被引文献29

  • 1赵玉沛,于学忠,白春梅,等.肿瘤内科诊疗常规[M].北京:人民卫生出版社,2012:109-113.
  • 2Shirvani SM, Jiang J, Gomez DR, et al. Intensity modulated radiothera- py for stage Ill non-small cell lung cancer in the United States : Predic- tors of use and association with toxicities[J]. Lung Cancer,2013,82 (2) :252-259.
  • 3Matsuo Y, Shibuya K, Nagata Y, et al. Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer[ J]. Int J Radiat On- col Biol Phys,2011,79(4) :1104-1111.
  • 4Fakiris A J, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radi- ation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study [ J ]. Int J Radiat Oncol Biol Phys ,2009,75 (3) :677-682.
  • 5Kundu S, Mathew A, Munshi A, et al. Stereotactic body radiotherapy in early stage non-small cell lung cancer: First experience from an Indian Centre[ J ]. Indian J Cancer,2013,50( 3 ) :227-232.
  • 6Cuaron JJ, Yorke ED, Foster A, et al. Stereotactic body radiation ther- apy for primary lung cancers > 3 centimeters [ J ]. J Thorac Oncol, 2013,8 ( 11 ) : 1396-1401.
  • 7Jeppesen SS,Schytte T,Jensen HR, et al. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on lo- cal failure and survival rates [ J]. Acta Oncol, 2013,52 ( 7 ) : 1552- 1558.
  • 8Liu YE, Lin Q, Meng FJ, et al. High-dose accelerated hypofraetionated three-dimensional eonformal radiotherapy (at 3 Gy/fraetian ) with concurrent vinorelbine and earboplatin chemotherapy in locally ad- vanced non-small-cell lung eaneer:a feasibility study [ J ]. Radiat On- eol,2013,8 ( 1 ) : 198.
  • 9Yamaguchi S, Ohguri T, Ide S, et al. Stereotactie body radiotherapy for lung tumors in patients with subclinical interstitial lung disease:The potential risk of extensive radiation pneumonitis [ J ]. Lung Cancer, 2013,82(2) :260-265.
  • 10Takahashi W, Yamashita H, Omori M, et al. The Feasibility and Effi- cacy of Stereotactie Body Radiotherapy for Centrally-located Lung Tumors[ J]. Antieancer Res,2013,33 ( 11 ) :4959-4964.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部